



## Dipartimento di Biotecnologie e Bioscienze – UNIMIB

Thursday, November 28, 2024, 4:30 p.m., TELLUS-U4 building, room U4-03

## Exploiting H-ferritin nanoconjugates to enhance cancer therapy

## <u>Linda Barbieri</u>

Department of Biotechnology and Biosciences University of Milano-Bicocca



**Abstract:** Recombinant heavy-chain ferritin (HFn) nanoparticles represent a promising platform for enhancing cancer treatments due to their multiple therapeutic advantages. HFn is biocompatible, can be loaded with drugs, and is easily modified via functional groups on its surface. Its tumor-targeting ability derives from recognizing transferrin receptor 1, overexpressed in 98% of solid cancers and linked to tumor progression. HFn also crosses the blood-brain barrier (BBB) through this same receptor, which is abundant on BBB endothelial cells. This seminar will discuss HFn's potential in treating glioblastoma and triple-negative breast cancer, with a focus on immunotherapeutic strategies.

Gli attestati di partecipazione al seminario sono validi anche per l'acquisizione dei CFU, per informazioni visitare la pagina del seminario btbs.unimib.it - LinkedIn: #BtBsUNIMIB - Twitter: @BtBsUNIMIB - YouTube channel: BtBsUNIMIB - infobtbs@unimib.it



Iscriviti alla mailinglist per i BtBs Seminars



Calendario BtBs Seminars 2024